Search the Newsreel

Insmed (INSM) Earnings Date and Reports 2026

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed Number of Employees 2026 | Employee Count & Headcount Data

Insmed, Inc. (NASDAQ: INSM) had approximately 1,713 employees worldwide as of March 2026, marking a 76.1% growth from 2023. The company is actively hiring, with 192 job postings in 2026, a 32.0% increase from 2025. Insmed's workforce is concentrated in North America, and the …

InvestingPro’s fair value predicted Insmed’s 45% decline 8 months early By Investing.com

InvestingPro's Fair Value analysis accurately predicted a significant decline in Insmed (NASDAQ:INSM) shares, flagging a 38.5% overvaluation eight months before the stock plummeted 44.66%. The analysis, which combines multiple sophisticated valuation methodologies, indicated the biopharmaceutical company's intrinsic worth was significantly lower than its trading …

Earnings Preview: Insmed to Report Financial Results Pre-market on August 06

Insmed (INSM) is scheduled to release its financial results on August 06 before market open. Analysts expect the company to report an EPS of -$0.36 and revenue of $69.75 million. This will be a key event for investors to assess the company's performance and …

Insmed Slips as Traders Appear to Await Earnings Despite Recent Positive Pipeline Updates

Insmed (INSM) shares are experiencing a decline as traders seem to be anticipating upcoming earnings, despite recent positive news regarding the company's pipeline. The stock has been trading with increased volume and has seen significant short interest, with a high short float and days …

Insmed Stock And 2 Healthcare Names To Watch As DOJ Uncertainty Builds

This article examines three healthcare stocks that are particularly sensitive to regulatory shifts, especially concerning the Department of Justice's policies and corporate taxation. With the nomination of a new U.S. Attorney General facing delays and increased scrutiny on DOJ settlements, companies like AnaptysBio, Insmed, …

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Insmed (INSM) is predicted to report a year-over-year increase in earnings and higher revenues for Q2 2026. The company is expected to post a quarterly loss of $0.69 per share with revenues of $389.72 million, surpassing previous estimates. A positive Earnings ESP of +22.32% …

Insmed Inc (INSM) Institutional Confidence

Insmed Inc (INSM) has a strong institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership has increased by 0.02% quarter-over-quarter, with Stanley Druckenmiller being the largest holder despite a slight decrease in his personal holdings. Several …

Insmed (INSM) Projected to Release Earnings on Thursday

Insmed Inc (INSM) Financial Health: Profitability & Balance Sheet Analysis

Insmed Inc (INSM) has a strong financial health score of 8.56, ranking 39th in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company reported a significant quarterly revenue increase of 229.62% year-over-year, reaching $305.96 million, with net …

INSM|Insmed Inc|Price:104.080|Chg%:-0.650

Insmed Inc (INSM) is currently trading at $104.08, down 0.62%. The company's fundamentals are strong with high growth potential, and it is considered fairly valued. Analysts have a "Buy" rating on the stock, with a target price of $196.96, indicating an 84.22% upside potential …

Cantor Fitzgerald reiterates Insmed stock rating on Brensupri sales outlook

Cantor Fitzgerald has reiterated an Overweight rating and a $235.00 price target for Insmed Inc. (NASDAQ:INSM), noting that the stock has remained flat as investors await upcoming catalysts. The firm estimates second-quarter Brensupri sales to be around $285 million, based on weekly script data, …

Insmed Inc (INSM) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Insmed Inc (INSM), covering operating, investing, and financing activities over several years. It includes specific financial figures and percentage changes for various cash flow components, along with a Q&A section defining different …

Insmed (INSM) TPIP Data Keeps Bull Case Alive As Valuation Debate Builds

Insmed (INSM) recently released promising 12-month open-label extension data for its treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension, showing sustained positive effects, which supports the ongoing Phase 3 study. Despite a recent share price decline, the stock has shown a significant 3-year …

Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Insmed Inc (INSM) has an earnings forecast score of 8.61, ranking 93rd in its industry, with an average analyst price target of USD 216.50. Analysts suggest a "Buy" trend based on 24 ratings. The expected revenue for the next quarter is USD 392.49 million, …

Insmed Inc (INSM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Insmed Inc's (INSM) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The page acts primarily as a placeholder …

Insmed Inc (INSM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Insmed Inc (INSM), highlighting its major shareholders and institutional holdings. Key data includes top shareholders like Darwin Global Management Ltd and JP Morgan Asset Management, categories of shareholder types (e.g., Investment Advisor, Hedge Fund), and changes in …

Insmed chair and CEO William Lewis sells over $1.1m in company stock

Insmed's Chair and CEO, William Lewis, sold over $1.1 million worth of company stock after exercising stock options. The transactions, executed under a pre-arranged trading plan, involved 10,700 shares at an average price near $106, following their acquisition at significantly lower exercise prices. Despite …

Insmed (INSM) CEO trades 10,700 shares after option exercise

Insmed Inc.'s Chair and CEO, William Lewis, executed stock options for 10,700 shares and subsequently sold the same amount under a Rule 10b5-1 trading plan on July 23, 2026. The shares were sold at weighted average prices of $105.62 and $106.43, resulting in approximately …

Insmed Incorporated Revenue Breakdown – LSE:0JAV

Insmed Incorporated (LSE:0JAV) reported a total revenue of $606.42 million USD last year. The "Therapies" segment was the top-performing contributor, generating the entirety of this revenue, a significant increase from $363.71 million USD in the prior year. The United States market was the primary …

Insmed Chair and CEO William Lewis disposes of 10,700 common shares worth $1.14 million

Insmed Chair and CEO William Lewis sold 10,700 shares on July 23 under a 10b5-1 plan, valuing the transaction at approximately $1.14 million. He also exercised stock options for 10,700 shares at lower prices. Following these transactions, his direct holdings total 259,058 shares, with …

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

Insmed Incorporated announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026. Management will host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Shareholders and interested parties can participate via phone or …

Form 144 INSMED INC For: 24 July By Investing.com

This article announces the filing of Form 144 by INSMED INC on July 24. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider trading activity. The brief announcement provides the stock symbol INSM and its current percentage change.

Insmed (INSM) insider William Lewis plans 10,700-share stock sale

Insmed Inc. (INSM) insider William Lewis has filed to sell 10,700 shares of common stock through Merrill Lynch, categorized as Stock Plan Activity, with the transaction dated July 23, 2026. The filing also details prior sales made by Lewis over the past three months, …

Insmed's second-quarter business update will be webcast Aug. 6

Insmed (NASDAQ: INSM) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026. The company will host a conference call for investors at 8:00 a.m. ET to discuss the results and provide a business update, with live access available via …

JPMorgan Chase & Co. (INSM) reports 10.37M Insmed shares, a 4.7% stake

JPMorgan Chase & Co. has reported a beneficial ownership of 10,365,622 shares of Insmed Incorporated common stock, constituting a 4.7% stake in the company. The filing specifies varying levels of sole and shared voting power, as well as dispositive power, maintained through several JPMorgan …

Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207

Guggenheim has maintained its Buy rating for Insmed (INSM.US) and reiterated a target price of $207. This indicates a continued positive outlook from the firm regarding Insmed's stock performance.

Insmed (INSM) Stock Could Be Pricey As Its 4.4x Run Continues

Insmed's stock has seen a significant 4.4x return over the past three years, but current valuation metrics suggest it might be overpriced. Despite positive 12-month data for treprostinil palmitil inhalation powder and progression to a Phase 3 trial, Insmed's price-to-sales (P/S) ratio of 28.7x …

INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192

BMO Capital has initiated coverage on Insmed (INSM) with an Outperform rating and a price target of $192.00, effective July 21, 2026. GuruFocus assesses INSM as 40.5% undervalued with a GF Value™ of $179.86 but cautions investors due to its classification as a "Possible …

INSM5182680 Bond Profile — Key Metrics

This article provides key metrics for the INSM5182680 bond issued by Insmed Incorporated. It details the bond's coupon rate, maturity date, issue date, and face value, along with a brief description of Insmed as a global biopharmaceutical company focusing on rare diseases.

Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension

Insmed Inc. announced positive 12-month data from its open-label extension (OLE) study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The study demonstrated sustained improvements across all secondary efficacy measures, including six-minute walk distance, NT-proBNP concentration, and WHO Functional Class, with …

BMO initiates Insmed stock with outperform rating on respiratory franchise potential

BMO Capital has initiated coverage on Insmed Inc. (NASDAQ:INSM) with an outperform rating and a $192 price target, citing the strong potential of its respiratory franchise, particularly Brinsupri and Arikayce. The firm projects significant peak sales for Brinsupri and highlights additional multi-billion-dollar pipeline optionality …

Buy Insmed for a double, this analyst says

Roth Capital Partners analyst Adam Walsh reiterated his "Buy" rating and $212.00 target on Insmed after the company released positive 12-month data from its TPIP extension study. The data showed durable improvement in six-minute walk distance for patients with pulmonary arterial hypertension, exceeding expectations …

Insmed stock price target maintained at $220 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $220 price target for Insmed (NASDAQ:INSM) following positive 12-month open-label extension data for its TPIP drug, indicating consistent efficacy and no new tolerability concerns. While this data de-risks the investment, the firm emphasizes that Phase …

Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?

Insmed (INSM) shares are in focus following positive 12-month data from an open-label extension study for treprostinil palmitil inhalation powder in pulmonary arterial hypertension. Despite recent share price volatility, analysts suggest Insmed is significantly undervalued, with a fair value of $197.14 against a current …